RadNet RDNT NASDAQ · Healthcare · United States
$76.42 +0.50% +$0.38
Summary
30 / 100 · Bulios Score
What speaks for it
- Revenue grew by 13% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 4.8 years of operating profit.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 13% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $22.4M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $65 is 15% below today's price. 83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Commercial Insurance1 59%
- Medicare1 25%
- Capitation Arrangements 6.5%
- Health Care, Other 3.4%
- Medicaid1 2.7%
- Other 3.8%
By region
- UNITED STATES 98%
- Non-US 1.7%
Commercial Insurance1 brings in 59% of revenue. Health Care, Other grew fastest, by 47% a year.
Segments in detail